Abstract:Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are effective in suppressing inflammation and preventing joint damage. But bDMARDs may be associated with increased risk of severe infection. Evidence on this is contradictory with some studies showing increased risk, whereas others reporting no significant changes. Objectives To determine the impact of the introduction of bDMARDs on severe infection among patients newly diagnosed with RA compared with non-RA individuals. Methods In this age- and gender-matched cohort study using administrative health data for the population of BC, Canada, all incident RA patients diagnosed between 1995–2007 were identified. Non-RA individuals were randomly selected from the general control population to match with RA. Incident RA/non-RA individuals were then divided into quarterly cohorts according to their diagnosis date. Two outcomes were examined: (1) first severe infection (FSI) after RA onset necessitating hospitalization or occurring during hospitalization; and (2) all severe infections (ASI) after RA onset. We calculated the 8-year FSI and ASI rate for each cohort. We conducted interrupted time-series analyses to compare levels and trends of FSI and ASI in RA and non-RA individuals diagnosed during pre-bDMARDs (1995–2001) and post-bDMARDs (2003–2007) periods. Adjusted 8-year FSI and ASI rates for RA and non-RA cohorts diagnosed five years after bDMARDs introduction were compared with expected rates assuming no bDMARDs introduction, based on extrapolation of pre-bDMARDs trends. Results A total of 60,226 and 588,499 incident RA/non-RA individuals were identified. We identified 8,954 FSI and 14,245 ASI in RA, and 56,153 FSI and 79,819 ASI in non-RA. The 8-year FSI rates among RA patients diagnosed in the pre-bDMARDs period decreased over time but leveled off among those diagnosed in the post-period (Figure 1). The adjusted difference between the post- and pre-bDMARDs secular trends of 8-year FSI rates was 0.68 (p=0.03) in RA and 0.03 (p=0.67) in non-RA (Table 1). The 8-year ASI rates among RA patients diagnosed in the pre-bDMARDs period decreased over time but increased significantly among those diagnosed in the post-period (Figure 1). The adjusted difference between the post- and pre-bDMARDs secular trends of 8-year ASI rates was 1.85 (p=0.001) in RA and 0.12 (p=0.29) in non-RA (Table 1). For RA cohort diagnosed 5 years after bDMARDs introduction, ASI rate increased by 20.4% than expected rates assuming no bDMARDs introduction. In contrast, ASI rate in non-RA increased by only 10.9%. Table 1. Results of interrupted time-series analysis of FSI/ASI rates, adjusting for age, gender, chronic obstructive pulmonary disease, Romano Charlson Comorbidity Index, diabetes, chronic kidney diseases, alcoholism, cancer, prior hospitalization with infection and socio-economic status at disease diagnosis year, using stepwise model selection Outcome Parameter RA Non-RA Unadj. Diff (95% CI) Adj. Diff (95% CI) Unadj. Diff (95% CI) Adj. Diff (95% CI) p-value p-value p-value p-value FSI Trend 0.63 (0.03, 1.22) 0.0441 0.68 (0.09, 1.27) 0.0292 0.08 (-0.08, 0.25) 0.3237 0.03 (-0.12, 0.19) 0.6728 Level (1 year post-intervention) 0.50 (-2.00, 2.99) 0.6989 0.31 (-1.88, 2.49) 0.7847 0.41 (-0.21, 1.03) 0.2041 0.26 (-0.24, 0.75) 0.3103 5 years post-intervention 3.01 (-0.85, 6.87) 0.1331 3.02 (-0.48, 6.52) 0.0986 0.75 (-0.24, 1.73) 0.1433 0.39 (-0.46, 1.25) 0.3721 ASI Trend 1.84 (0.83, 2.84) 0.0009 1.85 (0.81, 2.89) 0.0011 0.28 (0.04, 0.53) 0.0305 0.12 (-0.10, 0.34) 0.2877 Level (1 year post-intervention) -1.21 (-5.41, 3.00) 0.5763 -1.44 (-5.44, 2.56) 0.4850 1.46 (0.42, 2.49) 0.0085 1.20 (0.38, 2.02) 0.0064 5 years post-intervention 6.14 (0.26, 12.01) 0.0466 5.97 (0.02, 11.93) 0.0560 2.60 (1.08, 4.12) 0.0017 1.69 (0.45, 2.92) 0.0109 Figure 1. Unadjusted rates. Conclusion Arthritis onset after bDMARDs introduction is associated with an elevated risk of severe infection in RA patients, compared with matched non-RA individuals. Acknowledgements We would like to thank the Ministry of Health of British Columbia and Population Data BC for providing access to the administrative data. All inferences, opinions, and conclusions drawn in this publication are those of the authors, and do not reflect the opinions or policies of the Data Stewards or the [British Columbia] Ministry of Health. No personal identifying information was made available as part of this study. Procedures used were in compliance with British Columbia’s Freedom in Information and Privacy Protection Act. Ethics approval was obtained from the University of British Columbia’s Behavioral Research Ethics Board (H15-00887). Disclosure of Interests None declared.

Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review

Infections in Biological and Targeted Synthetic Drug Use in Rheumatoid Arthritis: Where do We Stand? A Scoping Review and Meta-analysis

Burden of non-serious infections during biological use for rheumatoid arthritis

Incidence of serious infections in the working-age Japanese adult population with rheumatoid arthritis treated with tumor necrosis factor-α inhibitors and interleukin-6 inhibitors: A nationwide retrospective cohort study

Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis

Risk of Severe Infections after the Introduction of Biologic DMARDs in People with Newly Diagnosed Rheumatoid Arthritis: a Population-Based Interrupted Time-Series Analysis

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database

Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis]

Incidences and risk factors of serious infections among different rheumatic patients: a retrospective cohort study

Risk factor of non-tuberculous Mycobacterium infection in patients with rheumatoid arthritis and other autoimmune diseases receiving biologic agents: A multicenter retrospective study

Predictors of serious infections in rheumatoid arthritis—a prospective Brazilian cohort

Meta-analysis of the risk of developing serious infections following treatment with tumor necrosis factor-α inhibitors for rheumatoid arthritis

Multiple morbidities are associated with serious infections in patients with rheumatoid arthritis

Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study

Risk of Tuberculosis During Infliximab Therapy for Inflammatory Bowel Disease, Rheumatoid Arthritis, and Spondyloarthropathy: A Meta-Analysis

Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study

The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia

OA20 Serious infections hospital admissions and mortality in patients with early inflammatory arthritis: results from the National Early Inflammatory Arthritis Audit

Safety issues and concerns of new immunomodulators in rheumatology

Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry

Results of a Retrospective, Multicenter Cohort Study